{"version":"1.0","provider_name":"Myanmar News Gazette","provider_url":"https:\/\/myanmarnewsgazette.com","author_name":"admin","author_url":"https:\/\/myanmarnewsgazette.com\/author\/admin\/","title":"Bright Peak Therapeutics Licenses Rights to Livzon\u2019s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines - Myanmar News Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jNFBBOTs3z\"><a href=\"https:\/\/myanmarnewsgazette.com\/bright-peak-therapeutics-licenses-rights-to-livzons-anti-pd-1-antibody-lzm009-to-develop-novel-pd-1-targeted-immunocytokines\/\">Bright Peak Therapeutics Licenses Rights to Livzon\u2019s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/myanmarnewsgazette.com\/bright-peak-therapeutics-licenses-rights-to-livzons-anti-pd-1-antibody-lzm009-to-develop-novel-pd-1-targeted-immunocytokines\/embed\/#?secret=jNFBBOTs3z\" width=\"600\" height=\"338\" title=\"&#8220;Bright Peak Therapeutics Licenses Rights to Livzon\u2019s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines&#8221; &#8212; Myanmar News Gazette\" data-secret=\"jNFBBOTs3z\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) \u2014 Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation cytokine immunotherapies, today announced that it has entered into a license agreement with Livzon Mabpharm, Inc. (\u201cLivzon\u201d), a subsidiary company of Livzon Pharmaceutical Group, to use LZM009, Livzon\u2019s proprietary anti-PD-1 monoclonal antibody currently in late-stage [\u2026]"}